An official website of the United States government
Initiate development of imaging and/or fluid biomarkers to demonstrate target engagement for 5 novel therapeutic targets for AD and AD-related dementias.
2030 PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting Progression (R01) PAR-16-266: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01) PAR-19-070: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) (Reissue of PAR-15-359) PAR-20-037: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) PAR-20-038: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) NOT-AG-22-032: Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) 9.C In Progress Initiate development of imaging and/or fluid biomarkers to demonstrate target engagement for 5 novel therapeutic targets for AD... DN 2012 AD Summit: 1E News: Imaging of brain synapses could be novel test for Alzheimer's Neuro-PET Radiotracer Discovery for Imaging Glycogen Synthase Kinase-3 Longitudinal Molecular Imaging of Neuropathology and Serotonin in Mild Cognitive Impairment In Vivo MRI Biomarkers of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer’s Disease Assessing Brain Microstructure in AD with Advanced Diffusion MRI CSF Clearance in Sporadic Alzheimer’s Disease The Longitudinal Course of Imaging Biomarkers in People at Risk of AD PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis Exploratory evaluation of [11C]MPC6827 Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia 2014
Identification of 3 imaging and/or fluid biomarkers for which there is proof of engagement of novel therapeutic targets.
Summary of Key Accomplishments
NIA supports biomarker discovery by academic institutions and small biotech companies through targeted and non-targeted funding initiatives. Seven new imaging biomarkers (five PET ligands and two MRI-based markers) reflecting synaptic function, oxidative stress, and neuroinflammation are being developed and evaluated in animal models and in humans. In addition, 28 projects have been funded that support the discovery of novel blood-based biomarkers using various genomic technologies.
The key accomplishments summary is current as of March 2022.